Trial reportHaematologica2011
Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial.
Trial report in Haematologica, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00447694 (An Open Label Trial Evaluating Cardiac T2* in Beta-thalassemia Patients on Deferasirox), which is not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open Label Trial Evaluating Cardiac T2* in Beta-thalassemia Patients on Deferasirox (ICL670) Treatment for 18 Months
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Pooled it
- Longitudinal monitoring of cardiac siderosis using cardiovascular magnetic resonance T2* in patients with thalassemia major on various chelation regimens: a 6-year study.American journal of hematology · 2013Trial
- Iron homeostasis and ferroptosis in muscle diseases and disorders: mechanisms and therapeutic prospects.Bone research · 2025Review
- Diagnostic Value of T1 Mapping in Detecting Iron Overload in Indian Patients with Thalassemia Major: A Comparison with T2* Mapping.The Indian journal of radiology & imaging · 2024Article
- Cardiac complications in thalassemia throughout the lifespan: Victories and challenges.Annals of the New York Academy of Sciences · 2023Review
- The role of MRI-R2* in the detection of subclinical pancreatic iron loading among transfusion-dependent sickle cell disease patients and correlation with hepatic and cardiac iron loading.Insights into imaging · 2022Article
- Modern management of iron overload in thalassemia major patients guided by MRI techniques: real-world data from a long-term cohort study.Annals of hematology · 2022Article
- Article
- Review
- Deferasirox: Over a Decade of Experience in Thalassemia.Mediterranean journal of hematology and infectious diseases · 2018Review
- Article
- Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin.Haematologica · 2017Article
- A Review on Iron Chelators in Treatment of Iron Overload Syndromes.International journal of hematology-oncology and stem cell research · 2016Review
- Acute cardiac decompensation in a patient with beta-thalassemia and diabetes mellitus following cessation of chelation therapy.Clinical case reports · 2016Article
- Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders.Haematologica · 2016Article
- Estimating tissue iron burden: current status and future prospects.British journal of haematology · 2015Review
- Use of magnetic resonance imaging to monitor iron overload.Hematology/oncology clinics of North America · 2014Review
- Measuring collective cell movement and extracellular matrix interactions using magnetic resonance imaging.Scientific reports · 2013Article
- On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The US04 trial was a multicenter, open-label, single arm trial of deferasirox monotherapy (30-40 mg/kg/day) for 18 months. Cardiac iron response was bimodal with improvements observed in patients with mild to moderate initial somatic iron stores; relationship of cardiac response to labile plasma iron is now presented. Labile plasma iron was measured at baseline, six months, and 12 months. In patients having a favorable cardiac response at 18 months, initial labile plasma iron was elevated in only 31% of patients at baseline and no patient at six or 12 months. Cardiac non-responders had elevated labile plasma iron in 50% of patients at baseline, 50% patients at six months, and 38% of patients at 12 months. Risk of abnormal labile plasma iron and cardiac response increased with initial liver iron concentration. Persistently increased labile plasma iron predicts cardiac non-response to deferasirox but labile plasma iron suppression does not guarantee favorable cardiac outcome. Study registered at www.clinicaltrials.gov (NCT00447694).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.